butyl(cyclohexyl)amine hydrochloride | 61278-99-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: butyl(cyclohexyl)amine hydrochloride
• 英文别名: N-butylcyclohexanamine hydrochloride；N-butylcyclohexanamine;hydrochloride
• CAS: 61278-99-7
• 化学式: C₁₀H₂₁N*ClH
• 分子量: 191.744
• InChiKey: WWDZNUWHIGDJRW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.13
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  环己酮 、 正丁胺 在 palladium on activated charcoal ammonium formate 作用下， 以 甲醇 、 水 为溶剂， 以72%的产率得到butyl(cyclohexyl)amine hydrochloride
  参考文献：
  名称：

  A modified palladium catalysed reductive amination procedure

  摘要：

  New, extended applications of a modified palladium catalysed reductive amination procedure are described; a mechanistic hypothesis alternative to the common imine pathway is proposed. This versatile method advances the usual reductive amination processes in terms of yield and shows high stereoselectivity whether applied to constrained carbonyl compounds. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(02)00530-6

文献信息

• [EN] TREATMENT OF CHAGAS DISEASE<br/>[FR] TRAITEMENT DE LA MALADIE DE CHAGAS
  申请人：UNIV DUNDEE

  公开号：WO2015189595A1

  公开（公告）日：2015-12-17

  The invention provides compounds of the formula: wherein L1 and L2 are independently selected from O and S; R1 is C3-C6straight or branched alkyl, C3-C7cycloalkyl, C5-C7cycloalkenyl, adamantly, phenyl or saturated heterocyclyl, any of which being optionally substituted; R2 is H, methyl or ethyl; R5 is NRxCORy, NRxRy, CH2COCH3, CH2C≡N, or a 5- or 6-membered heteroaryl group which is optionally substituted; X, Y and Z are independently N or CH; Rx is independently H or C1-C4alkyl; Ry is independently H, CrC4alkyl, phenyl or benzyl, either of which is optionally substituted; n is 0-3; salts, hydrates and N-oxides, wherein the optional substituents are further defined in the claims. The compounds have utility in the prophylaxis or treatment of trypanosomal diseases, such as T. cruzi (Chagas disease).

  该发明提供了以下式的化合物：其中L1和L2分别选自O和S；R1为C3-C6直链或支链烷基，C3-C7环烷基，C5-C7环烯基，脱氢胆固醇，苯基或饱和杂环烷基，其中任一可选择地被取代；R2为H，甲基或乙基；R5为NRxCORy，NRxRy，CH2COCH3，CH2C≡N，或者是可选择地被取代的5-或6-成员杂芳基团；X、Y和Z分别为N或CH；Rx分别为H或C1-C4烷基；Ry分别为H，CrC4烷基，苯基或苄基，其中任一可选择地被取代；n为0-3；盐、水合物和N-氧化物，其中可选择的取代基在权利要求中进一步定义。这些化合物在预防或治疗锥虫病等锥虫病方面具有用途。
• 7-Oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
  申请人：E.R. SQUIBB & SONS, INC.

  公开号：EP0374952A2

  公开（公告）日：1990-06-27

  7-Oxabicycloheptane substituted prostaglandin analogs which are thromboxane A2 (TxA2) receptor antagonists or combined thromboxane A2 receptor antagonists/thromboxane synthase inhibitors useful, for example, in treating thrombotic and vasospastic disease have the structural formula wherein m is 1, 2 or 3; n is 0, 1, 2, 3 or 4; Z is -(CH2)2- or -CH=CH-, with the proviso when Z is -CH = CH-, n is 1, 2, 3 or 4; R is C02H, CO2lower alkyl, CH2OH, CO2alkali metal, CONHSOR3, CONHR3a or -CH2-5-tetrazolyl, X is 0, S or NH; and where R1, R2, R3 and R3a are as defined herein.

  7-氧杂双环庚烷取代的前列腺素类似物是血栓素 A2（TxA2）受体拮抗剂或血栓素 A2 受体拮抗剂/血栓素合成酶联合抑制剂，可用于治疗血栓性疾病和血管痉挛性疾病等，其结构式为 其中 m 是 1、2 或 3；n 是 0、1、2、3 或 4；Z 是-(CH2)2- 或-CH=CH-，但当 Z 是-CH=CH-时，n 是 1、2、3 或 4；R 是 C02H、 lower 烷基、 OH、CO2 碱金属、CONHSOR3、CONHR3a 或- -5-四唑基，X 是 0、S 或 NH；其中 R1、R2、R3 和 R3a 如本文所定义。
• Interphenylène 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs useful in the treatment of thrombotic and vasopastic disease
  申请人：E.R. SQUIBB & SONS, INC.

  公开号：EP0391652A1

  公开（公告）日：1990-10-10

  Interphenylene 7-oxabicycloheptane substituted prostaglandin analogs are provided which are useful in treating thrombotic and vasospastic disease and have the structural formula wherein m is 1, 2 or 3; n is 0, 1, 2, 3 or 4; Y is O, vinyl or a single bond, with the proviso that when n is 0, Y is a single bond; R is CO₂H, CO₂alkali metal, CO₂lower alkyl, CH₂OH, CONHSO₂R³, CONHR3a or 5-tetrazolyl, with the proviso that when R is 5-tetrazolyl, n is other than 0; X is O, S or NH; R¹ is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl, aralkyl, cycloalkyl, cyclo­alkylalkyl, saturated heterocycle, saturated heterocyclicalkyl, aromatic heterocycle, aromatic heterocyclicalkyl or amido; each optionally substituted with an alkyl, aryl, cycloalkyl, or cycloalkylalkyl; and R² is hydrogen, lower alkyl, aryl, or aralkyl, or R¹ and R² together with the N to which they are linked form a 5- to 8- membered ring; R³ is lower alkyl, aryl or aralkyl and R3a is hydrogen, lower alkyl, aroyl or aralkyl.

  提供了可用于治疗血栓性和血管痉挛性疾病的间苯 7-氧杂双环庚烷取代的前列腺素类似物，其结构式为 其中 m为1、2或3 n 是 0、1、2、3 或 4； Y 是 O、乙烯基或单键，但当 n 为 0 时，Y 是单键； R 是 CO₂H、CO₂碱金属、CO₂低级烷基、CH₂OH、CONHSO₂R³、CONHR3a 或 5-四唑基，但当 R 是 5-四唑基时，n 不是 0； X 是 O、S 或 NH； R¹ 是氢、低级烷基、低级烯基、低级炔基、芳基、芳烷基、环烷基、环烷基烷基、饱和杂环基、饱和杂环烷基、芳香杂环基、芳香杂环烷基或氨基；每个基团可任选被烷基、芳基、环烷基或环烷基烷基取代；以及 R² 是氢、低级烷基、芳基或芳烷基，或 R¹ 和 R² 与它们连接的 N 一起形成一个 5 至 8 个成员的环； R³ 是低级烷基、芳基或芳烷基，R3a 是氢、低级烷基、芳基或芳烷基。
• 7-Oxabicycloheptyl substituted heterocyclic thioamide prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
  申请人：E.R. SQUIBB & SONS, INC.

  公开号：EP0476994A1

  公开（公告）日：1992-03-25

  7-Oxabicycloheptane substituted prostaglandin analogs useful in treating thrombotic and vasospastic disease have the structural formula wherein m is 1, 2 or 3; n is 1, 2, 3 or 4; Z is -(CH₂)₂-, -CH=CH- or wherein Y is O, a single bond or vinyl, with the proviso that when n is O, if Z is then Y cannot be O, and when Z is -CH=CH-, n is 1, 2, 3 or 4; and when Y=vinyl, n=0; R is CO₂H, CO₂lower alkyl, CH₂OH, CO₂alkali metal, CONHSOR³, CONHR3a or -CH₂-5-tetrazolyl, X is O, S or NH; and where R¹, R², R³ and R3a are as defined herein.

  可用于治疗血栓性和血管痉挛性疾病的 7-氧杂双环庚烷取代的前列腺素类似物的结构式为 其中 m 是 1、2 或 3；n 是 1、2、3 或 4；Z 是-(CH₂)₂-、-CH=CH- 或-(CH₂)₂-。 其中 Y 是 O、单键或乙烯基，但当 n 是 O 时，如果 Z 是 则 Y 不能为 O，当 Z 为-CH=CH-时，n 为 1、2、3 或 4；当 Y= 乙烯基时，n=0；R 为 CO₂H、CO₂低级烷基、CH₂OH、CO₂碱金属、CONHSOR³、CONHR3a 或-CH₂-5-四唑基，X 为 O、S 或 NH；其中 R¹、R²、R³ 和 R3a 如本文所定义。
• TREATMENT OF CHAGAS DISEASE
  申请人：UNIVERSITY OF DUNDEE

  公开号：US20170114029A1

  公开（公告）日：2017-04-27

  The invention provides compounds of the formula: wherein L 1 and L 2 are independently selected from O and S; R 1 is C 3 -C 6 straight or branched alkyl, C 3 -C 7 cycloalkyl, C 5 -C 7 cycloalkenyl, adamantly, phenyl or saturated heterocyclyl, any of which being optionally substituted; R 2 is H, methyl or ethyl; R 5 is NRxCORy, NRxRy, CH 2 COCH 3 , CH 2 C≡N, or a 5- or 6-membered heteroaryl group which is optionally substituted; X, Y and Z are independently N or CH; Rx is independently H or C 1 -C 4 alkyl; Ry is independently H, CrC4alkyl, phenyl or benzyl, either of which is optionally substituted; n is 0-3; salts, hydrates and N-oxides, wherein the optional substituents are further defined in the claims. The compounds have utility in the prophylaxis or treatment of trypanosomal diseases, such as T. cruzi (Chagas disease).